This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ilebekk, A. Articles by Nordlander, M. Search for Related Content PubMed PubMed Citation Articles by Ilebekk, A. Articles by Nordlander, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE CARBON DIOXIDE OXYGEN POTASSIUM Social Bookmarking                         What's this?

Ventricular Fibrillation Induced by Ischemia-Reperfusion Is Not Prevented by the NPY Y2 Receptor Antagonist BIIE0246

Institute for Experimental Medical Research, University of Oslo, Oslo, Norway, arnfinn.ilebekk{at}medisin.uio.no

Morten Eriksen

Institute for Experimental Medical Research, University of Oslo, Oslo, Norway

Knut Sevre, MD, PhD

Department of Cardiology, Ullevål University Hospital, Oslo, Norway

Trude Aspelin, BLS

Center for Clinical Research, Ullevål University Hospital, Oslo, Norway

Jan-Arne Björkman, MSc

Department of Integrative Pharmacology, AstraZeneca, Mölndal, Sweden

Torstein Lyberg, MD, PhD

Center for Clinical Research, Ullevål University Hospital, Oslo, Norway

Margareta Nordlander, PhD

Department of Integrative Pharmacology, AstraZeneca, Mölndal, Sweden

Neuropeptide Y is released together with norepinephrine from sympathetic nerve terminals during conditions of increased sympathetic activity. Neuropeptide Y is known to inhibit vagal activity, and accordingly, it might increase the risk for ventricular fibrillation during myocardial ischemia-reperfusion, with concomitant sympathetic stimulation. Counteracting the inhibiting effect of neuropeptide Y by the specific neuropeptide Y2 antagonist, BIIE0246, we expected occurrence of ventricular fibrillation in association with repeated periods of myocardial ischemia-reperfusion to decrease. The midleft anterior descending coronary artery was repeatedly occluded in 16 open-chest pigs. Eight pigs received BIIE0246, and the controls received the vehicle only. Ventricular fibrillation developed in 2 animals of the control group, but in 4 pigs receiving BIIE0246. Occurrence of ventricular fibrillation and ventricular tachycardia did not differ significantly between the 2 groups, and in association with repeated periods of regional myocardial ischemia, did not decline in pigs treated by the specific neuropeptide Y2-receptor antagonist BIIE0246.

Key Words: myocardial ischemia • neuropeptide Y2 antagonism • ventricular fibrillation

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 11, No. 3, 177-183 (2006)
DOI: 10.1177/1074248406292709


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?